A Phase 1 interventional study of Zanubrutinib and Tislelizumab in Lymphoma and Leukemia, sponsored by BeiGene. Completed at 10 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-07-01.
Sponsored by BeiGene · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 120 studies in Lymphoma with a site in Australia — 24 open to participants now, 40 under way, 15 of them phase 3. Lymphoma · Australia.
Among the 120 studies in Lymphoma with a site in Australia, this one is the 83rd largest by enrollment of the 116 interventional ones that give a count, is one of 2 that started in 2016, is one of 24 in phase 1, and was the 64th registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →24 of the 120 studies in Lymphoma with a site in Australia are open now. Recruiting first, the newest first:
Arovella Therapeutics Ltd · Sites in Australia
Ages 18+
AstraZeneca · Sites in Australia, United States, Canada and 2 more countries
Ages 18–18
ModeX Therapeutics, An OPKO Health Company · Sites in Australia, Israel, Spain
Ages 18+
Lyell Immunopharma, Inc. · Sites in Australia, United States, Canada
Ages 18+
Treeline Biosciences, Inc. · Sites in Australia, United States, Canada
Ages 18+
A study can be open while its sites in Australia have not opened yet or have stopped. Only those recruiting at a site in Australia →
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
120 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 42 · Phase 2 56 · Phase 3 44
First in 1994; this study’s year is marked. 2 started in 2016.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 75 is above the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 132 across the 116 interventional studies, 420 across the 1 observational. Of the 77 that completed or were terminated, 30 (39%) have results posted.
This tab as a report to print or save as PDF → With an account.
71 of 120 have an industry lead sponsor. The 10 most frequent:
This study is registered under BeiGene, one of the names counted as BeOne Medicines. Under that name alone:
BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.
Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.
BeOne Medicines has 6 studies filed under Lymphoma — fewer than ten, so there is no comparison to draw.
13 of the studies in Lymphoma with a site in Australia that are under way reach primary completion within a year, 9 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04529772Phase 3Acerta Pharma BVA Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) | 2027-02-22 |
| NCT07202078Phase 3Monash UniversityRole of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) | 2027-03-31 |
| NCT07202052Phase 3Monash UniversityRole of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Platform Trial (RATIONAL-PT) | 2027-03-31 |
| NCT07202091Phase 3Monash UniversityRole of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) | 2027-03-31 |
| NCT07202065Phase 3Monash UniversityRole of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Dosing Immunoglobulin (Dose Ig) | 2027-03-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 120 studies in Lymphoma with a site in Australia, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is evaluating the safety and preliminary efficacy of BGB-3111 in combination with BGB-A317 in participants with B-cell lymphoid malignancies.
Key Inclusion Criteria
Participants may be entered in the study only if they meet all of the following criteria:
Key Exclusion Criteria
Participants will not be entered in the study for any of the following reasons:
NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Histologically or cytologically confirmed
The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).
Your pathology report is the document that shows this.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Measurable disease
The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.
The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Based on results of the dose escalation cohorts and the identified recommended Phase 2 dose, all patients will receive zanubrutinib at 160 mg orally twice daily in combination with intravenous infusion of tislelizumab 200mg given every 21 days, to be continued until disease progression, unacceptable toxicity, treatment consent withdrawal, or study termination
Drug: Zanubrutinib · Drug: Tislelizumab
Also known as: BGB-3111, Brukinsa
Also known as: BGB-A317
Dose Escalation: Maximum Tolerated Dose (MTD) of Tislelizumab
The MTD of tislelizumab is considered the dose level below that at which at least 2 participants (or at least 33%) experience a dose-limiting toxicity (DLT).
Time frame: From the date of first dose of study drugs until RP2D was determined (Approximately 1 year and 10 months)
Dose Escalation: RP2D of Tislelizumab
The RP2D of tislelizumab in combination with zanubrutinib will be selected by taking into account the safety, tolerability, and pharmacokinetic (PK) profile.
Time frame: From the date of first dose of study drugs until final R2PD was decided (Approximately 1 year and 10 months)
Number of Participants With TEAEs and SAEs
A treatment-emergent adverse event (TEAE) was defined as an AE that had an onset date during the treatment emergent period, defined as from the first dose date of zanubrutinib or tislelizumab (whichever is earlier) through 30 days after the last dose (permanent discontinuation of study drug) of zanubrutinib or 90 days after the last dose of tislelizumab, whichever is later, or prior to initiation of new anti-cancer therapy. Treatment-related serious adverse events (SAEs) and any worsening of a TEAE by PT post treatment-emergent period were also counted as TEAEs.
Time frame: From the day of first dose of study drug until end of study (up to 4 years and 6 months)
Overall Response Rate
ORR, is defined as the percentage of participants who had complete response (CR) or partial response (PR) by standard disease-specific response criteria. for WM participants ORR includes minor response (MR) and very good partial response (VGPR).
Time frame: Up to 4 years and 6 months
Duration of Response (DOR)
DOR is defined as the time from the date that a confirmed objective response is first documented to the date of progressive disease (PD) or death due to any cause for those participants with a confirmed PR or CR.
Time frame: Up to 4 years and 6 months
Progression Free Survival (PFS)
PFS, is defined as the time from the first dose of study medication to objective disease progression or death
Time frame: Up to 4 years and 6 months
Number of Participants With Anti-Drug Antibodies (ADAs) to Tislelizumab
Time frame: From the day of first dose of study drug until end of study (up to 4 years and 6 months)
The study consisted of a dose escalation phase during which 3 dose levels of tislelizumab were administered in combination with a total of 320 mg zanubrutinib to determine the recommended phase 2 dose (RP2D). Once RP2D was determined all participants remaining in the study were switched to RP2D. A total of 75 participants were enrolled in both phases combined. As pre-specified in the protocol, analyses were conducted by disease subtype on the overall enrolled participants and not by phases.
| Milestone | Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 2.0 mg/kg Q3W | Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 5.0 mg/kg Q3W | Dose Escalation: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W | Dose Expansion: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W |
|---|---|---|---|---|
| Started | 15 | 10 | 7 | 43 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 15 | 10 | 7 | 43 |
| Withdrew: Death | 5 | 4 | 4 | 18 |
| Withdrew: Sponsor's decision at discontinuation and death at end of trial | 0 | 0 | 0 | 1 |
| Withdrew: Physician's decision at discontinuation and death at end of trial | 0 | 0 | 0 | 2 |
| Withdrew: Study ended by sponsor once primary and secondary objectives were met | 3 | 2 | 0 | 8 |
| Withdrew: Withdrawal by subject | 4 | 0 | 0 | 3 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 1 |
| Withdrew: Roll over to long term extension | 3 | 3 | 2 | 5 |
| Withdrew: Progressive disease | 0 | 1 | 0 | 4 |
| Withdrew: Physician decision | 0 | 0 | 0 | 1 |
The MTD of tislelizumab is considered the dose level below that at which at least 2 participants (or at least 33%) experience a dose-limiting toxicity (DLT).
| mg | Dose Escalation Phase |
|---|---|
| Dose Escalation: Maximum Tolerated Dose (MTD) of Tislelizumab | NA |
The RP2D of tislelizumab in combination with zanubrutinib will be selected by taking into account the safety, tolerability, and pharmacokinetic (PK) profile.
| mg | Dose Escalation Phase |
|---|---|
| Dose Escalation: RP2D of Tislelizumab | 200 |
A treatment-emergent adverse event (TEAE) was defined as an AE that had an onset date during the treatment emergent period, defined as from the first dose date of zanubrutinib or tislelizumab (whichever is earlier) through 30 days after the last dose (permanent discontinuation of study drug) of zanubrutinib or 90 days after the last dose of tislelizumab, whichever is later, or prior to initiation of new anti-cancer therapy. Treatment-related serious adverse events (SAEs) and any worsening of a TEAE by PT post treatment-emergent period were also counted as TEAEs.
| Number of participants | Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 2.0 mg/kg Q3W | Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 5.0 mg/kg Q3W | Dose Escalation: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W | Dose Expansion: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W |
|---|---|---|---|---|
| Participants With at Least One TEAE | 15 | 9 | 7 | 40 |
| Participants With at Least One SAE | 10 | 10 | 4 | 23 |
ORR, is defined as the percentage of participants who had complete response (CR) or partial response (PR) by standard disease-specific response criteria. for WM participants ORR includes minor response (MR) and very good partial response (VGPR).
| Percentage of participants | Other B-Cell Malignancies | GCB DLBCL | Non-GCB DLBCL | Richter's Transformation | Transformed Lymphoid Malignancy | PCNSL or SCNSL of Breast or Testicular Origin |
|---|---|---|---|---|---|---|
| Overall Response Rate | 37.5 (15.2 to 64.6) | 25.0 (5.5 to 57.2) | 40.0 (16.3 to 67.7) | 42.9 (9.9 to 81.6) | 40 (19.1 to 63.9) | 40 (5.3 to 85.3) |
DOR is defined as the time from the date that a confirmed objective response is first documented to the date of progressive disease (PD) or death due to any cause for those participants with a confirmed PR or CR.
| Months | Other B-Cell Malignancies | GCB DLBCL | Non-GCB DLBCL | Richter's Transformation | Transformed Lymphoid Malignancy | PCNSL or SCNSL of Breast or Testicular Origin |
|---|---|---|---|---|---|---|
| Duration of Response (DOR) | 22.36 (7.72 to NA) | NA (NA to NA) | 6.79 (2.36 to NA) | 17.47 (2.96 to NA) | 8.89 (2.83 to NA) | 7.80 (7.06 to 8.55) |
PFS, is defined as the time from the first dose of study medication to objective disease progression or death
| Months | Other B-Cell Malignancies | GCB DLBCL | Non-GCB DLBCL | Richter's Transformation | Transformed Lymphoid Malignancy | PCNSL or SCNSL of Breast or Testicular Origin |
|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) | 16.94 (5.39 to NA) | 1.43 (0.57 to NA) | 2.80 (1.43 to 6.99) | 2.93 (2.43 to 20.33) | 4.68 (1.26 to 8.52) | 8.42 (0.33 to 16.07) |
| Number of participants | Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 2.0 mg/kg Q3W | Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 5.0 mg/kg Q3W | Dose Escalation: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W | Dose Expansion: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W |
|---|---|---|---|---|
| Treatment Emergent ADA | 0 | 0 | 0 | 1 |
| Neutralizing antibody Positive | 0 | 0 | 0 | 0 |
Collected over From the Day of first dose of study drug until end of Study (up to 4 years and 6 months). Non-serious events are listed at a 3% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 2.0 mg/kg | 5/15 (33.3%) | 10/15 (66.7%) | 15/15 (100%) |
| Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 5.0 mg/kg | 4/10 (40%) | 10/10 (100%) | 9/10 (90%) |
| Dose Escalation: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W | 4/7 (57.1%) | 4/7 (57.1%) | 7/7 (100%) |
| Dose Expansion: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W | 21/43 (48.8%) | 23/43 (53.5%) | 40/43 (93%) |
| Event | Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 2.0 mg/kg | Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 5.0 mg/kg | Dose Escalation: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W | Dose Expansion: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W |
|---|---|---|---|---|
| PyrexiaGeneral disorders | 0/15 | 2/10 | 0/7 | 0/43 |
| PneumoniaInfections and infestations | 1/15 | 2/10 | 0/7 | 1/43 |
| Haemolytic transfusion reactionInjury, poisoning and procedural complications | 0/15 | 2/10 | 0/7 | 0/43 |
| Immune-mediated enterocolitisGastrointestinal disorders | 0/15 | 1/10 | 1/7 | 1/43 |
| Drug hypersensitivityImmune system disorders | 0/15 | 0/10 | 1/7 | 0/43 |
| SepsisInfections and infestations | 0/15 | 0/10 | 1/7 | 0/43 |
| HypercalcaemiaMetabolism and nutrition disorders | 0/15 | 0/10 | 1/7 | 0/43 |
| AnaemiaBlood and lymphatic system disorders | 0/15 | 1/10 | 0/7 | 1/43 |
| Atypical haemolytic uraemic syndromeBlood and lymphatic system disorders | 0/15 | 1/10 | 0/7 | 0/43 |
| Multiple organ dysfunction syndromeGeneral disorders | 0/15 | 1/10 | 0/7 | 2/43 |
| Event | Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 2.0 mg/kg | Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 5.0 mg/kg | Dose Escalation: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W | Dose Expansion: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W |
|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 6/15 | 2/10 | 2/7 | 10/43 |
| FatigueGeneral disorders | 5/15 | 2/10 | 0/7 | 9/43 |
| Upper respiratory tract infectionInfections and infestations | 5/15 | 3/10 | 1/7 | 5/43 |
| NauseaGastrointestinal disorders | 4/15 | 3/10 | 1/7 | 7/43 |
| HeadacheNervous system disorders | 1/15 | 3/10 | 0/7 | 4/43 |
| CoughRespiratory, thoracic and mediastinal disorders | 4/15 | 3/10 | 0/7 | 7/43 |
| Urinary tract infectionInfections and infestations | 1/15 | 0/10 | 2/7 | 6/43 |
| RashSkin and subcutaneous tissue disorders | 2/15 | 1/10 | 2/7 | 3/43 |
| ContusionInjury, poisoning and procedural complications | 2/15 | 2/10 | 0/7 | 10/43 |
| AnaemiaBlood and lymphatic system disorders | 2/15 | 1/10 | 0/7 | 9/43 |
Safety analysis set includes all participants who receive at least 1 dose of zanubrutinib and/or tislelizumab.
| Age, Continuous(years) | Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 2.0 mg/kg Q3W | Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 5.0 mg/kg Q3W | Dose Escalation: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W | Dose Expansion: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W | Total |
|---|---|---|---|---|---|
| Mean | 60.4 ± 12.63 | 60.7 ± 6.52 | 70.4 ± 5.26 | 66.7 ± 9.85 | 65.0 ± 10.20 |
| Sex: Female, Male(Participants) | Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 2.0 mg/kg Q3W | Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 5.0 mg/kg Q3W | Dose Escalation: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W | Dose Expansion: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W | Total |
|---|---|---|---|---|---|
| Female | 4 | 5 | 4 | 16 | 29 |
| Male | 11 | 5 | 3 | 27 | 46 |
| Ethnicity (NIH/OMB)(Participants) | Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 2.0 mg/kg Q3W | Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 5.0 mg/kg Q3W | Dose Escalation: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W | Dose Expansion: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 0 | 1 | 1 |
| Not Hispanic or Latino | 12 | 7 | 7 | 38 | 64 |
| Unknown or Not Reported | 3 | 3 | 0 | 4 | 10 |
| Race/Ethnicity, Customized(Participants) | Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 2.0 mg/kg Q3W | Dose Escalation: Zanubrutinib 320 mg QD + Tislelizumab 5.0 mg/kg Q3W | Dose Escalation: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W | Dose Expansion: Zanubrutinib 160 mg BID + Tislelizumab 200 mg Flat Q3W | Total |
|---|---|---|---|---|---|
| Race- White | 14 | 9 | 7 | 33 | 63 |
| Race - Asian | 1 | 1 | 0 | 9 | 11 |
| Race - Other | 0 | 0 | 0 | 1 | 1 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes
Ran from Jun 2016 to primary completion in Dec 2020, 53 months.
Results were first posted in Jul 2022, 1 year 6 months after primary completion.
Of 143 industry-sponsored phase 1 interventional studies under Lymphoma, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 61. This study's 53 months is above that.
Counting every sponsor, half of 281 studies reached it within 53 months; a quarter within 34 and three quarters within 77.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Zanubrutinib · Tislelizumab